How Darzalex Targets Multiple Myeloma Cells
Darzalex (daratumumab) is a monoclonal antibody that binds to CD38, a protein overexpressed on multiple myeloma cells. This binding triggers the body's immune system to attack and destroy the cancer cells through three main mechanisms: antibody-dependent cellular cytotoxicity (ADCC), where natural killer cells and macrophages kill the targeted cells; complement-dependent cytotoxicity (CDC), where the complement system forms pores in the cell membrane leading to lysis; and antibody-dependent cellular phagocytosis (ADCP), where immune cells engulf and digest the myeloma cells.[1][2]
It also inhibits myeloma cell growth directly by blocking CD38's enzymatic activity, which disrupts adenosine production and impairs the tumor cells' ability to evade immune detection.[1]
How It's Given and Used in Treatment
Darzalex is administered intravenously or subcutaneously, often in combination with drugs like bortezomib, lenalidomide, or dexamethasone. It's approved for newly diagnosed, relapsed, or refractory multiple myeloma, either as monotherapy after multiple prior therapies or with regimens like RVd (Revlimid, Velcade, dexamethasone) for frontline use. Treatment cycles typically start weekly, then space out to monthly maintenance.[2][3]
Clinical Outcomes and Response Rates
In trials like POLLUX and CASTOR, Darzalex combos extended progression-free survival by 12-18 months over standard therapies, with overall response rates of 80-93% versus 60-70% without it. Minimal residual disease negativity rates reached 25-64%, correlating with longer remissions.[3][4]
Common Side Effects Patients Experience
Infusion-related reactions occur in 35-50% of patients, mostly during the first dose (chills, nausea, cough), managed with pre-medications like steroids and antihistamines. Other issues include fatigue (40%), anemia (30%), and infections (25%), due to immune modulation. Subcutaneous dosing reduces reaction rates to under 10%.[2][3]
How It Fits with Other Myeloma Therapies
Darzalex complements proteasome inhibitors (e.g., Velcade) and immunomodulators (e.g., Revlimid) by hitting a different pathway, improving depth of response in triplets or quadruplets like Dara-RVd. It's less effective alone in heavily pretreated patients (response ~30%), but shines in combos. Stem cell transplant patients often use it post-transplant for maintenance.[3][4]
Who Makes Darzalex and Access Details
Janssen (Johnson & Johnson) manufactures Darzalex, approved by FDA in 2015 for relapsed myeloma and expanded since. Patents extend exclusivity into the 2030s; check DrugPatentWatch.com for expiry dates and challenges.[5]
[1] https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/761032s044lbl.pdf
[2] https://www.darzalex.com/multiple-myeloma/about-darzalex
[3] https://www.nejm.org/doi/full/10.1056/NEJMoa1902219
[4] https://pubmed.ncbi.nlm.nih.gov/28170425/
[5] https://www.drugpatentwatch.com/p/tradename/DARZALEX